DexCom, Inc. (DXCM) Gross Margin: 61.84%
Is DexCom, Inc.’s gross margin high or low?
DexCom, Inc.'s gross margin of 61.84% is in line with its 5-year average of 63.91%, near the low end of its 5-year range (60.01%–68.63%).
The gross margin for DexCom, Inc. (DXCM) is 61.84% as of Wednesday, June 10, 2026. It is above its 12-month average by 2.66% (60.23%).
DXCM Gross Margin Chart
DXCM Average Gross Margin Chart
DXCM Current vs Average Gross Margin Chart
DXCM Gross Margin Metrics
GROSS MARGIN
61.84%
GROSS MARGIN AVG TTM
60.23%
GROSS MARGIN AVG 3Y
62.09%
GROSS MARGIN AVG 5Y
63.91%
GROSS MARGIN AVG 10Y
64.97%
GROSS MARGIN AVG 15Y
61.05%
GROSS MARGIN AVG 20Y
16.79%
CURRENT VS TTM AVG
+2.66%
CURRENT VS 3Y AVG
-0.41%
CURRENT VS 5Y AVG
-3.24%
CURRENT VS 10Y AVG
-4.82%
CURRENT VS 15Y AVG
+1.29%
CURRENT VS 20Y AVG
+268.28%
DXCM Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | — | 61.84% | 60.23% | 62.09% | 63.91% |
| Biogen Inc. (BIIB) | $29.00B | 69.77% | 73.30% | 74.61% | 77.63% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 26.11% | 30.59% | 32.75% | 33.07% |
| Veeva Systems Inc. (VEEV) | $27.37B | 75.53% | 75.03% | 73.28% | 73.00% |
| Centene Corporation (CNC) | $31.94B | 14.93% | 11.28% | 11.33% | 11.71% |
| Zoetis Inc. (ZTS) | $34.20B | 70.75% | 69.79% | 68.91% | 68.46% |
| Waters Corporation (WAT) | $23.83B | 55.02% | 58.60% | 58.69% | 58.45% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 57.79% | 57.84% | 57.54% | 57.23% |
| BioNTech SE (BNTX) | $21.81B | 73.26% | 78.98% | 81.24% | 82.89% |
| Agilent Technologies, Inc. (A) | $38.26B | 52.43% | 53.36% | 52.95% | 53.14% |
Gross Margin Analysis
Gross Margin
61.8%
(Revenue - COGS) / Revenue
DexCom, Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Gross Margin FAQ
- What is the gross margin for DexCom, Inc. (DXCM)?
- The gross margin for DXCM stock is 61.84%.
- Is DexCom, Inc.'s gross margin high or low?
- DexCom, Inc.'s gross margin of 61.84% is in line with its 5-year average of 63.91%, near the low end of its 5-year range (60.01%–68.63%).
- What is the TTM average gross margin for DexCom, Inc. (DXCM)?
- The TTM average gross margin for DXCM stock is 60.23%.
- What is the 3Y average gross margin for DexCom, Inc. (DXCM)?
- The 3Y average gross margin for DXCM stock is 62.09%.
- What is the 5Y average gross margin for DexCom, Inc. (DXCM)?
- The 5Y average gross margin for DXCM stock is 63.91%.
- What is the 10Y average gross margin for DexCom, Inc. (DXCM)?
- The 10Y average gross margin for DXCM stock is 64.97%.
- What is the 15Y average gross margin for DexCom, Inc. (DXCM)?
- The 15Y average gross margin for DXCM stock is 61.05%.
- What is the 20Y average gross margin for DexCom, Inc. (DXCM)?
- The 20Y average gross margin for DXCM stock is 16.79%.
DexCom, Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 60.01% |
| 2024-12-31 | 60.46% |
| 2023-12-31 | 63.19% |
| 2022-12-31 | 64.72% |
| 2021-12-31 | 68.63% |
| 2020-12-31 | 66.44% |
| 2019-12-31 | 63.11% |
| 2018-12-31 | 64.36% |
| 2017-12-31 | 68.49% |
| 2016-12-31 | 66.00% |
| 2015-12-31 | 69.25% |
| 2014-12-31 | 68.02% |
| 2013-12-31 | 62.56% |
| 2012-12-31 | 46.65% |
| 2011-12-31 | 47.00% |
| 2010-12-31 | 37.92% |
| 2009-12-31 | 12.33% |
| 2008-12-31 | -56.20% |
| 2007-12-31 | -175.25% |
| 2006-12-31 | -405.07% |
| 2005-12-31 | 0.00% |
| 2004-12-31 | 0.00% |
| 2003-12-31 | 0.00% |
| 2002-12-31 | 0.00% |
| 2001-12-31 | 0.00% |
| 2000-12-31 | 0.00% |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach